Share

Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma

AI: Melanie Research RF Safe Research Library Jan 1, 2021 NEUTRAL LOW

This pooled case series evaluated amplitude-modulated 27.12 MHz RF EMF delivered via the TheraBionic P1 device (3 hours daily) in patients with advanced hepatocellular carcinoma, comparing outcomes to historical controls. The authors report longer median overall survival for Child-Pugh A patients versus comparable historical controls and similar/slightly higher survival for certain Child-Pugh B comparisons. Reported adverse events were mild (grade 1 mucositis and fatigue) with no discontinuations due to adverse events.

Key points

  • The intervention delivered 27.12 MHz RF EMF systemically using a tongue-placed antenna device.
  • Design was a pooled case series including 18 real-world patients and 41 patients from a previously reported phase II study.
  • Outcomes included overall survival, time to progression, response rate, and adverse events.
  • Median overall survival was reported by Child-Pugh class, with Child-Pugh A showing longer survival than comparable historical controls.
  • Adverse events reported were limited to grade 1 mucositis and fatigue.
  • No patients discontinued treatment because of adverse events.
  • The comparison group consisted of historical controls from previously conducted clinical trials.

Referenced studies & papers

Source: Open original

AI-generated summaries may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.